02/21/2020
In this podcast, Gregory Krauss, MD, discusses his research on cenobamate as adjunctive therapy for adults with uncontrolled focal seizures, how the results of this research aided in cenobamate's approval by the US Food and Drug Administration, and more.
Note: Dr Krauss notes that medications have low responder and seizure-free rates and that cenobamate was much more effective in regulatory trials. To be more specific, Dr Krauss clarifies that other add-on treatments or other drugs used to treat resistant focal-onset seizures had relatively low responses.
Gregory L. Krauss, MD, is a professor of neurology and epileptologist at Johns Hopkins Medicine in Baltimore, Maryland.
Additional Resources:
- Balbi A. FDA approves new option for adults with partial-onset seizures [published online November 21, 2019]. Neurology Consultant. https://www.consultant360.com/exclusive/neurology/epilepsy/fda-approves-new-option-adults-partial-onset-seizures.
- Krauss GL, Klein P, Brandt C, et al. Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial [published online November 13, 2019]. Lancet Neurol. https://doi.org/10.1016/S1474-4422(19)30399-0.